3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
161
Neoplasm Metastasis
22
Neoplasms
20
Advanced Breast Cancer
13
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Hereditary Sensory and Autonomic Neuropathies
9
Endometrial Neoplasms
8
Triple Negative Breast Neoplasms
7
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
5
Recurrence
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Breast Diseases
4
Small Cell Lung Carcinoma
3
Head and Neck Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Liposarcoma
2
HER2-positive Metastatic Breast Cancer
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Interventions
relacorilant
1
pembrolizumab
1
dapagliflozin
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hyperglycemia
×
Fulvestrant
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts